Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Options Action: Naked Put Trade Ideas for March 31

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

First, let’s find some stocks with above average implied volatility.

Fundamentals

See More
  • Market Capitalization, $K 169,228,192
  • Shares Outstanding, K 1,241,222
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,022 M
  • EBITDA $ 12,782 M
  • 60-Month Beta 0.36
  • Price/Sales 5.66
  • Price/Cash Flow 12.82
  • Price/Book 7.36

Options Overview Details

View History
  • Implied Volatility 32.40% (-1.06%)
  • Historical Volatility 22.03%
  • IV Percentile 68%
  • IV Rank 38.42%
  • IV High 49.97% on 04/08/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 2) 5.21 (3.78%)
  • Put/Call Vol Ratio 0.38
  • Today's Volume 2,411
  • Volume Avg (30-Day) 13,746
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 150,265
  • Open Int (30-Day) 151,973
  • Expected Range 132.75 to 143.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.86
  • Number of Estimates 9
  • High Estimate 1.97
  • Low Estimate 1.73
  • Prior Year 1.81
  • Growth Rate Est. (year over year) +2.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.89 +2.85%
on 03/30/26
150.77 -8.67%
on 03/02/26
-11.24 (-7.55%)
since 02/27/26
3-Month
116.88 +17.82%
on 01/05/26
157.29 -12.45%
on 02/11/26
+13.01 (+10.43%)
since 12/26/25
52-Week
93.37 +47.48%
on 04/25/25
157.29 -12.45%
on 02/11/26
+25.92 (+23.18%)
since 03/28/25

Most Recent Stories

More News
Options Action: Naked Put Trade Ideas for March 31

With market volatility on the rise, put premiums are highly elevated, so it’s a good time to check in on Barchart’s Naked Put Screener.

INTC : 43.38 (+5.32%)
MU : 330.59 (+2.73%)
FCX : 57.94 (+6.02%)
GILD : 137.88 (+1.13%)
DAL : 65.55 (+3.73%)
S&P Futures Waver as Concerns Over Middle East Conflict Persist, U.S. PMI Data in Focus

June S&P 500 E-Mini futures (ESM26) are trending up +0.02% this morning, swinging between gains and losses as optimism over a de-escalation in the Middle East conflict wanes.

APO : 111.14 (+1.08%)
AVGO : 306.86 (+4.58%)
JEF : 41.06 (+3.58%)
CCL : 25.45 (+6.22%)
ASML : 1,303.85 (+3.98%)
FICO : 1,066.75 (+1.79%)
ESM26 : 6,485.50 (+1.52%)
CRWV : 75.17 (+8.71%)
TSLA : 369.92 (+4.12%)
NCLH : 18.45 (+4.53%)
PUIG.E.DX : 16.920 (-0.35%)
RL : 341.15 (+4.45%)
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead Intends...

GILD : 137.88 (+1.13%)
3 Reasons to Avoid GILD and 1 Stock to Buy Instead

3 Reasons to Avoid GILD and 1 Stock to Buy Instead

GILD : 137.88 (+1.13%)
2 Mega-Cap Nasdaq Stocks with Unusual Options Activity: What to Watch

By taking advantage of Barchart’s scanning tools and doing a small bit of legwork, investors can gain powerful insights.

META : 564.84 (+5.31%)
TSLA : 369.92 (+4.12%)
GILD : 137.88 (+1.13%)
Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Arcellx , Inc....

ACLX : 114.70 (-0.06%)
GILD : 137.88 (+1.13%)
3 Top-Rated Stocks to Buy to Hedge Against Stagflation as Middle East Conflict Drags On

Amid widespread uncertainties, these three names can shield your portfolio.

KO : 75.63 (-0.84%)
GILD : 137.88 (+1.13%)
ET : 19.46 (-0.66%)
3 Blue-Chip Stocks Built for a Rotating Market

Investors are rotating out of overvalued mega-cap tech as the broader economy heats up; these three blue-chip stocks are attracting attention

DUK : 130.81 (-0.68%)
GILD : 137.88 (+1.13%)
HSY : 206.70 (-3.21%)
These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.

V : 298.35 (-0.40%)
GILD : 137.88 (+1.13%)
ABBV : 216.27 (+1.48%)
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

– Grants to Strengthen Prevention Models and Local Systems of Care Nationwide –

GILD : 137.88 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 140.09
2nd Resistance Point 138.36
1st Resistance Point 137.35
Last Price 137.88
1st Support Level 134.61
2nd Support Level 132.88
3rd Support Level 131.87

See More

52-Week High 157.29
Last Price 137.88
Fibonacci 61.8% 132.87
Fibonacci 50% 125.33
Fibonacci 38.2% 117.79
52-Week Low 93.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.